Biomarkers /
GATA2
Overview
GATA binding protein 2 (GATA2) is a gene that encodes a zinc-finger transcription factor in the GATA family. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions and insertions are observed in cancers such as colorectal cancer, lung cancer, and skin cancer.
GATA2 is altered in 1.13% of all cancers with colon adenocarcinoma, lung adenocarcinoma, acute myeloid leukemia, prostate adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in GATA2 are GATA2 Mutation (0.84%), GATA2 Exon 3 Mutation (0.37%), GATA2 Amplification (0.16%), GATA2 Exon 5 Mutation (0.13%), and GATA2 Exon 4 Mutation (0.11%) [3].
Clinical Trials
Significance of GATA2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.